Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.
Natalie M ReizineKeith DanaheyTien M TruongDavid GeorgeLarry K HouseTheodore G KarrisonXander M R van WijkKiang-Teck J YeoMark J RatainPeter H O'DonnellPublished in: Cancer (2022)
Differences in our genes may explain why some drugs work safely in certain individuals but can cause side effects in others. Pharmacogenomics is the study of how genetic variations affect an individual's response to medications. In this study, an evaluation was done for important genetic variations that can affect the tolerability of anticancer therapy. By analyzing the genetic results of >1500 patients, it was found that nearly one-third have genetic variations that could alter recommendations of what drug, or how much of, an anticancer therapy they should be given. Performing pharmacogenomic testing before prescribing could help to guide personalized oncology care.
Keyphrases
- genome wide
- primary care
- palliative care
- copy number
- end stage renal disease
- chronic kidney disease
- adverse drug
- clinical decision support
- newly diagnosed
- ejection fraction
- randomized controlled trial
- emergency department
- dna methylation
- stem cells
- quality improvement
- mesenchymal stem cells
- chronic pain
- health insurance
- study protocol
- placebo controlled